BiondVax Pharmaceuticals Stock Forecast, Price & News

-0.15 (-4.87 %)
(As of 04/20/2021 12:00 AM ET)
Today's Range
Now: $2.93
50-Day Range
MA: $3.84
52-Week Range
Now: $2.93
Volume179,771 shs
Average Volume906,717 shs
Market Capitalization$33.27 million
P/E RatioN/A
Dividend YieldN/A
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which is in Phase III clinical trials for treatment of seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
BiondVax Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BVXV
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value($2.88) per share


Net Income$-31,600,000.00


Market Cap$33.27 million
Next Earnings Date6/29/2021 (Estimated)
OptionableNot Optionable


BiondVax Announces Appointment of Amir Reichman as New CEO
January 21, 2021 |
Why BiondVax Pharmaceuticals Stock Imploded Today
October 31, 2020 |
/C O R R E C T I O N -- BiondVax Pharmaceuticals Ltd./
October 23, 2020 |
Biondvax Pharmaceuticals Ltd - ADR
September 2, 2020 |
BiondVax Pharmaceuticals Ltd. (BVXV)
September 2, 2020 |
BiondVax Announces Second Quarter 2020 Financial Results
August 20, 2020 |
Keep an eye on the momentum at Biondvax Pharmaceuticals
July 24, 2020 |
See More Headlines


Overall MarketRank

0.50 out of 5 stars

Medical Sector

1558th out of 2,018 stocks

Biological Products, Except Diagnostic Industry

163rd out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.15 (-4.87 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BiondVax Pharmaceuticals (NASDAQ:BVXV) Frequently Asked Questions

What stocks does MarketBeat like better than BiondVax Pharmaceuticals?

Wall Street analysts have given BiondVax Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BiondVax Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 629,800 shares, a decrease of 18.4% from the March 15th total of 772,000 shares. Based on an average daily trading volume, of 979,100 shares, the days-to-cover ratio is presently 0.6 days.
View BiondVax Pharmaceuticals' Short Interest

When is BiondVax Pharmaceuticals' next earnings date?

BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, June 29th 2021.
View our earnings forecast for BiondVax Pharmaceuticals

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its quarterly earnings results on Thursday, January, 28th. The company reported ($0.01) earnings per share for the quarter.
View BiondVax Pharmaceuticals' earnings history

How has BiondVax Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

BiondVax Pharmaceuticals' stock was trading at $6.5350 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BVXV stock has decreased by 55.2% and is now trading at $2.93.
View which stocks have been most impacted by COVID-19

Who are BiondVax Pharmaceuticals' key executives?

BiondVax Pharmaceuticals' management team includes the following people:
  • Dr. Ron Babecoff D.V.M., DVM, Co-Founder, Pres & Sr. Advisor (Age 59)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 51)
  • Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 39)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 57)
  • Mr. Amir Reichman M.B.A., M.Sc., CEO & Director
  • Dr. Shimon Hassin, Chief Admin. Officer
  • Mr. Joshua E. Phillipson B.Sc., M.B.A., Director of Bus. Devel. & Investor Relations

Who are some of BiondVax Pharmaceuticals' key competitors?

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $2.93.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals has a market capitalization of $33.27 million. The company earns $-31,600,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does BiondVax Pharmaceuticals have?

BiondVax Pharmaceuticals employs 25 workers across the globe.

What is BiondVax Pharmaceuticals' official website?

The official website for BiondVax Pharmaceuticals is

Where are BiondVax Pharmaceuticals' headquarters?

BiondVax Pharmaceuticals is headquartered at Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]

This page was last updated on 4/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.